Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment.

Aponte PM, Caicedo A.

Stem Cells Int. 2017;2017:5619472. doi: 10.1155/2017/5619472. Epub 2017 Apr 4. Review.

2.

Human Lung Spheroids as In Vitro Niches of Lung Progenitor Cells with Distinctive Paracrine and Plasticity Properties.

Chimenti I, Pagano F, Angelini F, Siciliano C, Mangino G, Picchio V, De Falco E, Peruzzi M, Carnevale R, Ibrahim M, Biondi-Zoccai G, Messina E, Frati G.

Stem Cells Transl Med. 2017 Mar;6(3):767-777. doi: 10.5966/sctm.2015-0374. Epub 2016 Sep 22.

3.

A network-based pathway-expanding approach for pathway analysis.

Zhang Q, Li J, Xie H, Xue H, Wang Y.

BMC Bioinformatics. 2016 Dec 23;17(Suppl 17):536. doi: 10.1186/s12859-016-1333-x.

4.

Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells.

Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R.

Mol Cancer. 2017 Feb 1;16(1):28. doi: 10.1186/s12943-017-0595-x. Review.

5.

NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells.

Zhong Y, Shen S, Zhou Y, Mao F, Lin Y, Guan J, Xu Y, Zhang S, Liu X, Sun Q.

Onco Targets Ther. 2016 Nov 7;9:6865-6871. eCollection 2016.

6.

ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.

Strietz J, Stepputtis SS, Preca BT, Vannier C, Kim MM, Castro DJ, Au Q, Boerries M, Busch H, Aza-Blanc P, Heynen-Genel S, Bronsert P, Kuster B, Stickeler E, Brabletz T, Oshima RG, Maurer J.

Oncotarget. 2016 Dec 13;7(50):83278-83293. doi: 10.18632/oncotarget.13086.

7.

The V-ATPase a2 isoform controls mammary gland development through Notch and TGF-β signaling.

Pamarthy S, Mao L, Katara GK, Fleetwood S, Kulshreshta A, Gilman-Sachs A, Beaman KD.

Cell Death Dis. 2016 Nov 3;7(11):e2443. doi: 10.1038/cddis.2016.347.

8.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

9.

EMT in Breast Carcinoma-A Review.

Felipe Lima J, Nofech-Mozes S, Bayani J, Bartlett JM.

J Clin Med. 2016 Jul 14;5(7). pii: E65. doi: 10.3390/jcm5070065. Review.

10.

Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.

Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C, Cheng N.

Oncotarget. 2016 Aug 2;7(31):49349-49367. doi: 10.18632/oncotarget.9885.

11.

Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin.

Ono M, Takimoto R, Osuga T, Okagawa Y, Hirakawa M, Yoshida M, Arihara Y, Uemura N, Hayasaka N, Miura S, Matsuno T, Tamura F, Sato Y, Sato T, Iyama S, Miyanishi K, Takada K, Kobune M, Kato J.

Oncotarget. 2016 Jun 21;7(25):38586-38597. doi: 10.18632/oncotarget.9558.

12.

Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

Li Z, Kang Y.

Pharmacol Ther. 2016 May;161:79-96. doi: 10.1016/j.pharmthera.2016.03.003. Epub 2016 Mar 19. Review.

13.

Endothelial Transdifferentiation of Tumor Cells Triggered by the Twist1-Jagged1-KLF4 Axis: Relationship between Cancer Stemness and Angiogenesis.

Chen HF, Wu KJ.

Stem Cells Int. 2016;2016:6439864. doi: 10.1155/2016/6439864. Epub 2015 Dec 28. Review.

14.

New Findings on Breast Cancer Stem Cells: A Review.

Bozorgi A, Khazaei M, Khazaei MR.

J Breast Cancer. 2015 Dec;18(4):303-12. doi: 10.4048/jbc.2015.18.4.303. Epub 2015 Dec 23. Review.

15.

Targeting the Notch signaling pathway in cancer therapeutics.

Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J.

Thorac Cancer. 2014 Nov;5(6):473-86. doi: 10.1111/1759-7714.12143. Epub 2014 Oct 23. Review.

16.

Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression.

Phan NL, Trinh NV, Pham PV.

Onco Targets Ther. 2015 Dec 23;9:49-59. doi: 10.2147/OTT.S96291. eCollection 2016.

17.

Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.

Ryoo IG, Lee SH, Kwak MK.

Oxid Med Cell Longev. 2016;2016:2428153. doi: 10.1155/2016/2428153. Epub 2015 Nov 22. Review.

18.

Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy.

Borah A, Raveendran S, Rochani A, Maekawa T, Kumar DS.

Oncogenesis. 2015 Nov 30;4:e177. doi: 10.1038/oncsis.2015.35. Review.

19.

Notch-1 promotes breast cancer cells proliferation by regulating LncRNA GAS5.

Pei J, Wang B.

Int J Clin Exp Med. 2015 Aug 15;8(8):14464-71. eCollection 2015.

20.

Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.

Kim B, Stephen SL, Hanby AM, Horgan K, Perry SL, Richardson J, Roundhill EA, Valleley EM, Verghese ET, Williams BJ, Thorne JL, Hughes TA.

BMC Cancer. 2015 Sep 11;15:634. doi: 10.1186/s12885-015-1625-y.

Supplemental Content

Support Center